Literature DB >> 32536549

Vaccination using inactivated Mycoplasma pneumoniae induces detrimental infiltration of neutrophils after subsequent infection in mice.

Shigeyuki Tamiya1, Eisuke Yoshikawa1, Monami Ogura2, Etsushi Kuroda3, Koichiro Suzuki4, Yasuo Yoshioka5.   

Abstract

Mycoplasma pneumoniae (Mp) is one of the most common causes of community-acquired pneumonia. Given the emergence and high rates of antibiotic-resistant Mp strains, vaccines that prevent the pneumonia and secondary complications due to Mp infection are urgently needed. Although several studies have shown the protective efficacy of Mp vaccines in human clinical trials, some reports suggest that vaccination against Mp exacerbates disease upon subsequent Mp challenge. Therefore, to develop optimal vaccines against Mp, understanding the immune responses that contribute to post-vaccination exacerbation of inflammation is crucial. Here we examined whether Mp vaccination might exacerbate pneumonia after subsequent Mp infection in mice. We found that vaccination with inactivated Mp plus aluminum salts as an adjuvant induced Mp-specific IgG, Th1 cells, and Th17 cells. Toll-like receptor 2 signaling contributed to the induction of an Mp-specific IgG response and was necessary for Mp-specific Th17-cell-but not Th1-cell-responses in vaccinated mice. In addition, vaccination with inactivated Mp plus aluminum salts suppressed the number of Mp organisms in the bronchoalveolar lavage fluid, indicating that vaccination can reduce Mp infection. However, the numbers of total immune cells and neutrophils in bronchoalveolar lavage fluid after Mp challenge did not differ between vaccinated mice and non-vaccinated control mice. Furthermore, depletion of CD4+ T cells prior to Mp challenge decreased pulmonary neutrophil infiltration in vaccinated mice, suggesting that Th1 or Th17 cells (or both) are responsible for the vaccination-induced neutrophil infiltration. These results suggest that, despite reducing Mp infection, vaccination of mice by using inactivated Mp fails to suppress inflammation, such as neutrophil infiltration into the lung, after subsequent Mp infection.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Mycoplasma pneumoniae; Neutrophil; Pneumonia; Th17; Toll-like receptor 2; Vaccine

Mesh:

Year:  2020        PMID: 32536549     DOI: 10.1016/j.vaccine.2020.05.074

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Effect of bronchofiberscopic lavage with budesonide suspension on refractory mycoplasma pneumoniae pneumonia.

Authors:  Ya Li; Wei Yang; Xin Wu; Xiaohua Gou
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 2.340

2.  Susceptibility Analysis in Several Mouse Strains Reveals Robust T-Cell Responses After Mycoplasma pneumoniae Infection in DBA/2 Mice.

Authors:  Shigeyuki Tamiya; Eisuke Yoshikawa; Koichiro Suzuki; Yasuo Yoshioka
Journal:  Front Cell Infect Microbiol       Date:  2021-01-13       Impact factor: 5.293

Review 3.  Mycoplasma pneumoniae Infections: Pathogenesis and Vaccine Development.

Authors:  Zhulin Jiang; Shuihong Li; Cuiming Zhu; Runjie Zhou; Polly H M Leung
Journal:  Pathogens       Date:  2021-01-25

4.  Neutrophil-Mediated Lung Injury Both via TLR2-Dependent Production of IL-1α and IL-12 p40, and TLR2-Independent CARDS Toxin after Mycoplasma pneumoniae Infection in Mice.

Authors:  Shigeyuki Tamiya; Eisuke Yoshikawa; Monami Ogura; Etsushi Kuroda; Koichiro Suzuki; Yasuo Yoshioka
Journal:  Microbiol Spectr       Date:  2021-12-22

5.  Vaccination with Mycoplasma pneumoniae membrane lipoproteins induces IL-17A driven neutrophilia that mediates Vaccine-Enhanced Disease.

Authors:  Arlind B Mara; Tyler D Gavitt; Edan R Tulman; Jeremy M Miller; Wu He; Emily M Reinhardt; R Grace Ozyck; Meagan L Goodridge; Lawrence K Silbart; Steven M Szczepanek; Steven J Geary
Journal:  NPJ Vaccines       Date:  2022-07-29       Impact factor: 9.399

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.